Champions Oncology collaborates on breast and colon cancer co-clinical PDX studies

18 June 2018

Champions Oncology (Nasdaq: CSBR) has partnered with the NSABP Foundation (formerly National Surgical Adjuvant Breast and Bowel Project) and Puma Biotechnology (Nasdaq: PBYI) to develop patient derived xenograft (PDX) models in two multi-center co-clinical PDX trials.

The first trial, NSABP FB10 is a Phase II study evaluating the combination of trastuzumab emtansine (T-DM1; with Puma’s Nerlynx (neratinib) in women with metastatic HER2-positive breast cancer (NCT02236000) and is currently enrolling patients. Nerlynx is a rival to Kadcyla (trastuzumab emtansine) marketed by Roche)

Financial details of the collaboration were not disclosed, but Puma’s shares were down 2.19% at $53.50 in premarket trading this morning, while those of Champions, which is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, were up 1.01% at $6.01 shortly after markets opened.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK